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The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic myelogenous leukemia in
chronic phase (CML-CP) has revolutionized therapy, altering the outcome from one of shortened life expectancy to
long-term survival. With over 10 years of long-term treatment with imatinib and several years of experience with
the next generation of TKIs, including nilotinib, dasatinib, bosutinib, and ponatinib, it is becoming clear that many
clinical parameters have great impact on the prognosis of patients with CML. Emerging novel gene expression
profiling and molecular techniques also provide new insights into CML pathogenesis and have identified potential
prognostic markers and therapeutic targets. This review presents the supporting data and discusses how certain
clinical characteristics at diagnosis, the depth of early response, the presence of certain kinase domain mutations,
and additional molecular changes serve as prognostic factors that may guide individualized treatment decisions for
patients with CML-CP.
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Chronic myelogenous leukemia (CML) is a clonal mye-
loproliferative neoplasm caused by constitutive activa-
tion of the BCR-ABL1 tyrosine kinase, a result of the t
(9;22)(q34;q11) translocation designated the Philadelphia
(Ph) chromosome [1]. Treatment targeting this kinase
has proven to be highly successful. The introduction of
imatinib, the first BCR-ABL1 tyrosine kinase inhibitor
(TKI), overturned the treatment paradigm for CML [2,3]
by extending survival in patients who maintain durable
response to continued imatinib therapy [4,5].
Although imatinib represented a major therapeutic ad-
vance, the need for additional treatments was recognized
and addressed by the development of the more potent
BCR-ABL1 TKIs nilotinib, dasatinib, bosutinib, and po-
natinib (Table 1). Nilotinib and dasatinib were approved
for first-line treatment of Ph + CML in chronic phase
(CP) based on results of separate phase 3 studies indicat-
ing superior cytogenetic and molecular response rates
compared with imatinib [6-9]. Three- and 4-year data
from both studies continue to demonstrate significantly* Correspondence: javier.pinilla@moffitt.org
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reproduction in any medium, provided the orgreater response rates for nilotinib and dasatinib versus
imatinib [10-12].
With 3 TKIs currently available for front line therapy
and 2 more TKIs for second- and third-line therapy,
questions arise regarding which agent should be used,
and when, to optimize long-term outcomes. Numerous
patient- and drug-related factors, in addition to financial
considerations, contribute to decisions on treatment se-
lection. Emerging evidence suggests that certain clinical
characteristics at diagnosis, the depth of early response,
the presence of certain kinase domain (KD) mutations,
and additional molecular changes may impact the prog-
nosis of CML patients. This review examines various
prognostic factors in CML and explores the practical
utility of these prognostic factors in guiding treatment
decisions for patients with CML-CP both now and in
the future.Prognostic indicators at diagnosis
Prognostic scoring systems. CML prognostic scoring sys-
tems stratify patients into risk groups based on patient-
and disease-related characteristics at diagnosis. Until
recently, there were 2 widely used scoring systems, Sokal
and Hasford (Table 2). Introduced in 1984, the Sokaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




Imatinib 2001 CP, AP, or BC after failure of interferon therapy
2003 Newly diagnosed CP
Dasatinib 2006 CP, AP, or BC after resistance to or intolerance
of imatinib
2010 Newly diagnosed CP
Nilotinib 2007 CP or AP after resistance to or intolerance
of imatinib
2010 Newly diagnosed CP
Bosutinib 2012 CP, AP, or BC after resistance to or intolerance
of prior therapy
Ponatinib 2012 CP, AP, or BC after resistance to or intolerance
of prior TKI therapy
AP accelerated phase, BC blast crisis, CML chronic myelogenous leukemia,
CP chronic phase, FDA Food and Drug Administration, TKI tyrosine kinase
inhibitor, US United States.
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chemotherapy (busulfan or hydroxyurea) into 3 risk
groups, each with significantly different predicted long-
term survival [13]. With wider use of interferon-α for
early-stage CML, the Sokal score lost prognostic utility
and the Hasford score was developed [14].
In 2011, the European Treatment and Outcome Study
(EUTOS) score was introduced to reflect current standard
use of first-line imatinib (Table 2) [15]. In a comparative

















Exp 0.0116 (age – 43) + 0 .0345 (spleen size [cm below
costal margin] – 7.5 cm) + 0.188 [(platelet count/700)2 –






Risk groupsa •High: score > 1.2 •H
•Intermediate: score 0.8-1.2 •In
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aAn intermediate risk category is not defined for EUTOS.Hasford scores at predicting complete cytogenetic re-
sponse (CCyR) at 18 months (positive predictive value,
34%; sensitivity, 23%; specificity, 92%) and progression-
free survival (PFS) at 5 years (sensitivity, 16%; specificity,
91%) [15]. In an analysis of the German CML-Study IV,
EUTOS classification (high versus low risk) significantly
correlated with achievement of major molecular response
(MMR) and complete molecular response (CMR) [16].
Not all groups have been able to validate the EUTOS
score, however. An analysis from Hammersmith Hos-
pital of 277 imatinib-treated patients found that Sokal
score, but not EUTOS score, predicted overall survival
(OS), PFS, CCyR, and MMR [17]. The MD Anderson
Cancer Center group showed that EUTOS score was not
successful at predicting outcomes (MMR, transform-
ation-free survival, event-free survival [EFS], or OS) in
an analysis of CML-CP patients treated with imatinib
(n = 279), nilotinib (n = 98), or dasatinib (n = 88) [18].
Disparate conclusions about the utility of the EUTOS
score may be due to differences in patient populations
evaluated or its inapplicability to patients receiving
first-line nilotinib or dasatinib.
The applicability of Sokal and Hasford scores for pa-
tients receiving newer TKIs is also unclear. In the
Evaluating Nilotinib Efficacy and Safety in Clinical Tri-
als–Newly Diagnosed Patients (ENESTnd) study, nilo-
tinib-treated patients had higher rates of MMR, CMR,
and CCyR by 24 months than imatinib-treated patients,
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Patients (DASISION) study found higher 24-month MMR
rates with dasatinib versus imatinib across Hasford risk
categories [19]. Interestingly, in both the ENESTnd and
DASISION studies, patients who progressed in the
imatinib arms were categorized as intermediate or high
risk patients per the respective scoring systems. In the
Bosutinib Efficacy and Safety in Newly Diagnosed CML
(BELA) study, patients on bosutinib had higher rates of
12-month MMR than patients on imatinib, regardless
of Sokal risk category [20].
These findings suggest that the parameters used in
these prognostic scoring systems are limited, mostly
clinically oriented, and not directly related to genetic or
molecular indicators. Nevertheless, because high-risk
patients in the ENESTnd and DASISION studies ex-
perienced less disease progression on nilotinib and
dasatinib, respectively, than on imatinib, NCCN Guide-
lines recommend determination of Sokal or Hasford
risk status as part of the initial workup and the use of
nilotinib or dasatinib in high-risk patients [5]. Further
validation of the EUTOS score will also be necessary
before it is used in routine practice.
“Real-world” prognostic factors. Most data regarding
imatinib use are from clinical studies; data from real-
world settings are sparse. A recent study investigated
prognostic factors associated with achievement of com-
plete hematologic response, CCyR, MMR, and CMR in
1063 patients on first-line imatinib treatment who had
not participated in clinical studies [21]. Low Sokal risk
score, age <45 years, and African-American ethnicity
were associated with better outcomes [21]. How widely
considered these specific prognostic factors are in rou-
tine risk assessment and whether they are applicable to
nilotinib- or dasatinib-treated patients are unknown.
Prognostic impact of additional cytogenetic aberrations
(ACAs). ACAs are documented in 10%-15% of newly
diagnosed patients before TKI treatment [22]. In a retro-
spective analysis of the German CML Study IV, patients
with “major route” ACAs, including an additional Ph
chromosome, trisomy 8, isochromosome 17q, and tri-
somy 19 [23,24], at diagnosis had significantly longer
median times to CCyR and MMR, and reduced 5-year
PFS and OS compared to patients without ACAs [24].
Other studies have demonstrated that CML-CP patients
who developed ACAs during imatinib treatment had
significantly worse outcomes than patients who did not
[25]. The emergence of ACAs during treatment signifies
clonal evolution and, by definition, disease transform-
ation to accelerated phase/blast crisis (AP/BC) [26,27].
Current guidelines recommend bone marrow cytogen-
etic testing at diagnosis, when patients respond inad-
equately to first-line treatment, and when patients show
increasing disease burden [5]. The presence of ACAs,especially major-route abnormalities, at diagnosis may
indicate high risk for poor prognosis and may justify the
use of a next-generation TKI over imatinib as initial
therapy.
Variant translocations. Nearly all patients with CML
have a BCR-ABL1 fusion gene from the t(9;22)(q34;q11)
translocation. Approximately 5%-10% of patients, how-
ever, have more complex rearrangements involving chro-
mosomes 9, 22, and one or more additional chromosomes
[28]. Many variants have been identified, highlighting
the genetic heterogeneity of these patients [29-32]. The
prognostic significance of variant translocations remains
controversial [30,31,33-35], however, and requires fur-
ther study. Thus, this parameter has not yet been
widely applied in treatment decision-making for pa-
tients with CML.
BCR-ABL1 transcript: e13a2 (b2a2) versus e14a2
(b3a2). Most mRNAs transcribed from BCR-ABL1 have
either an e13a2 or e14a2 junction. Although both
mRNAs encode the p210 product of BCR-ABL1 [36,37],
the e14a2 transcript positively correlates with response.
In one study, patients with the e14a2 transcript achieved
higher rates of CCyR at 12 months and achieved CCyR
more rapidly than patients with the e13a2 transcript
[37]. In another study, MMR and MR4 (BCR-ABL1 ≤
0.01%) were achieved more rapidly by patients with the
e14a2 versus the e13a2 transcript [38]. At present, this
parameter is not widely used in routine practice, in large
part because many commercial molecular testing labora-
tories do not report the type of BCR-ABL1 transcript.
Furthermore, although these data are suggestive, further
investigation will be necessary to conclusively determine
the prognostic utility of BCR-ABL1 transcript type.
Pharmacokinetics. The organic cation transporter-1
(OCT-1) is the major transporter of imatinib into CML
cells [39]. OCT-1 activity, which reflects the degree of
imatinib influx, can predict long-term risk of resistance
and transformation [40]. Patients with high OCT-1 ac-
tivity were significantly more likely to achieve MMR by
5 years, and have significantly higher OS and EFS rates
and lower KD mutation rates than patients with low
activity. Although OCT-1 activity may predict imatinib
failure, it is unlikely to affect the response to nilotinib,
dasatinib, or ponatinib, as influx of these drugs does not
rely on OCT proteins [39,41,42]. The effect of OCT-1
acitivity on bosutinib influx is unknown [43]. The meas-
urement of OCT-1 activity level is currently limited to clin-
ical research and is not yet considered routine practice.
Imatinib plasma levels may correlate with treatment
response. In one study, mean imatinib trough levels were
significantly higher in patients who achieved CCyR and
MMR than in patients who did not (1123 versus 694 ng/
mL, P = 0.03) [44]. An exploratory analysis from the Inter-
national Randomized Study of Interferon and STI571
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CCyR, MMR, and EFS [45]. Some subsequent studies have
confirmed these findings; others have not [45-48]. Because
the clinical benefit of treatment change based on TKI
plasma levels is unproven, current guidelines do not
recommend routine monitoring of this sort [5].
Prognosis based on early treatment response: landmark
analyses
Landmark analyses assess treatment responses at fixed
timepoints and correlate them with future endpoints or
clinical outcomes. Landmark analysis of the IRIS study
found that molecular responses at 6, 12, and 18 months
predicted outcomes at 7 years [49]. The 7-year PFS rate
was 99% for patients who attained MMR by 12 or
18 months, compared with 90% for patients who did
not. Rates of 7-year EFS were 95%, 86%, and 65% in
patients who achieved MMR, BCR-ABL1 >0.1% to ≤1.0%
per the international scale (IS), and BCR-ABL1IS >1.0%,
respectively, at 18 months [49]. These data suggested
that response kinetics are important, with rapid and
deep molecular responses predicting excellent long-term
outcomes.
In particular, molecular response to TKI therapy at
3 months predicts future molecular response and long-
term survival outcomes, including OS (Table 3) [50,51].
In one landmark analysis of imatinib-treated patients,
BCR-ABL1 transcript level at 3, 6, and 12 months pre-
dicted the 8-year rates of CCyR, MMR, CMR, OS, PFS,
and EFS, but only BCR-ABL1 transcript level at 3 months
was found to be an independent predictor of 8-year
survival outcomes (Figure 1) [51].
Other studies have found evidence supporting the
prognostic significance of achieving molecular response
at 3 months in patients treated with imatinib, nilotinib,
dasatinib, or bosutinib (Table 3). Notably, early responses
in these studies were predictive of positive long-term
outcomes, irrespective of TKI received. Furthermore,
the newer TKIs produced faster molecular responses
than imatinib, which is consistent with data from the
ENESTnd, DASISION, and BELA trials [7,9,20,22,52-55].
Based on strong evidence that rapid, deep molecular
responses predict favorable long-term outcomes, the
National Comprehensive Cancer Network Clinical Prac-
tice Guidelines in Oncology (version 4.2013) have in-
corporated, for the first time, a molecular response goal
of BCR-ABL1 ≤10% at 3 months [5]. The newer TKIs
are superior to imatinib in eliciting rapid response, but
longer-term experience with the newer TKIs in the
front-line setting will be necessary to help guide treat-
ment decisions. Furthermore, the NCCN Guidelines
recommend that patients not reaching the goal of BCR-
ABL1 ≤10% at 3 months be considered for a treatment
change—in other words, replacing their current therapywith an alternative TKI. At present, however, the long-
term clinical benefit of an early switch in treatment re-
mains under investigation.
Predictive utility of mutational analysis
Point mutations in the BCR-ABL1 KD are a key mechan-
ism of resistance [56]. Most KD mutations acquired dur-
ing imatinib treatment confer resistance and predict poor
prognosis. The presence of KD mutations often portends
disesase progression, especially when patients do not
respond to second-line TKI therapy. Thus, the NCCN
Guidelines recommend that mutational analysis be done
when patients show inadequate initial response to TKI
therapy, or when there is evidence of relapse or disease
progression [5].
Regarding primary resistance, attempts to identify KD
mutations at diagnosis have been unsuccessful to date
because such TKI-resistant subclones exist at levels too
low to be detectable using conventional methodologies
[57,58]. Although the presence of mutations at low levels
may or may not predict poor prognosis [59], an expert
panel convened by the European LeukemiaNet has never-
theless recommended that newly diagnosed patients with
advanced disease be tested for mutations [56].
A more-sensitive technique for detecting TKI-resistant
clones has been developed: a multiplexed mass spectrom-
etry assay [60]. This method has been used to detect
nilotinib- and/or dasatinib-resistant mutations in patients
with imatinib resistance, including clinically relevant mu-
tations that were not detectable by direct sequencing [60].
Validation of this technique for detecting low-level muta-
tions in patients at diagnosis would help guide the most
appropriate front-line TKI and, in the case of a multi–
drug-resistant mutation, consideration of appropriate
therapy.
Advances in identifying molecular markers of progression
Identification of potentially important disease mediators
is an active area of research that employs techniques
such as gene microarray profiling and proteomic ana-
lysis. An in-depth exploration of the potential biological
significance of the molecules identified is beyond the
scope of this review. They are nevertheless mentioned to
provide a glimpse of what the future may bring in terms
of potential prognostic indicators and therapeutic targets.
Microarray profiling has been used to determine whe-
ther the specific gene expression at diagnosis can predict
the response to TKI treatment [61]. Analysis of CD34+
cells from newly diagnosed, treatment-naive patients
with CML-CP has revealed a 75-transcript signature (50
upregulated and 25 downregulated transcripts) that
predicted major cytogenetic response at 12 months with
an overall accuracy of 87% — exceeding the predictive
ability of the Sokal score [62]. Notably, 62% of the
Table 3 Summary of 3-month landmark analyses of selected clinical studies of first-line TKI therapy
TKI Study Parameter BCR-ABL1% (IS) at 3 months P value
Imatinib Hammersmith Hospital [51] ≤9.84% (n = 211) >9.84% (n = 68)
8-year OS 93.3% 56.9% <0.001
≤9.54% (n = 208) >9.54% (n = 71)
8-year PFS 92.8% 57.0% <0.001
≤8.58% (n = 169) >8.58% (n = 79)
8-year CCyR 99.4% 21.7% <0.001
≤2.81% (n = 141) >2.81% (n = 137)
8-year MMR 82.5% 21.1% <0.001
German CML Study IV [50] >1-10% (n = 281) >10% (n = 189)
5-year OS 92% 87% 0.037
>1-10% (n = 283) >10% (n = 191)
5-year PFS 94% 87% 0.012
ENESTnda [52] ≤10% (n = 176) >10% (n = 88)
MMR by 2 years 58% 21% NR
PFS at 3 years 97.7% 83.8%
OS at 3 years 98.9% 84.8%
DASISIONa [9] ≤10% (n = 154) >10% (n = 85)
AP/BC by 3 years 2.6% 12.9% NR
PFS at 3 years 95.9% 75.3% <0.0001
OS at 3 years 96.0% 88.0% 0.0036
BELAa [53] ≤10% (n = 146) >10% (n =77)
MMR by 24 months 69% 17% <0.001
CCyR by 12 months 95% 65% <0.001
OS at 24 months 99% 95% NS
Nilotinib ENESTnd [52] ≤10% (n = 234) >10% (n = 24)
MMR by 2 years 80% 29% NR
PFS at 3 years 95.9% 82.9%
OS at 3 years 97.6% 86.7%
Dasatinib DASISION [9] ≤10% (n = 198) >10% (n = 37)
AP/BC by 3 years 3.0% 13.5% NR
PFS at 3 years 93.1% 68.2% 0.0003
OS at 3 years 95.9% 85.9% 0.0348
Bosutinib BELA [53] ≤10% (n = 179) >10% (n =29)
MMR by 24 months 74% 21% <0.001
CCyR by 12 months 96% 48% <0.001
OS at 24 months 99% 88% 0.004
aData for the imatinib arm of the study.
AP/BC accelerated phase/blast crisis, CCyR complete cytogenetic response, MMR major molecular reponse, NR not reported, NS not significant, OS overall survival,
PFS progression-free survival.
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WNT/β-catenin pathway, which is activated during BC.
Thus, gene expression profiling at diagnosis may be
useful for identifying poor-prognosis patients and for
elucidating the biological basis of CML disease progres-
sion [62].
Radich et al. used gene microarrays to explore
what changes in gene expression are associated withprogression to AP/BC. Their group identified compo-
nents of the WNT/β-catenin pathway and alternative
kinase pathways, transcription factors JUN-B and FOS,
and the marker PRAME as being associated with ad-
vanced CML [63]. Further research identified a 6-gene
signature (NOB1, DDX47, IGSF2, LTB4R, SCARB1, and
SLC25A3) that discriminated between patients in CP and
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Figure 1 Transcript levels predict survival outcomes. Eight-year
probability of OS for patients stratified by risk group defined by
transcript levels at 3 months (high-risk BCR-ABL1/ABL1 ratio > 9.84%
[n = 68; gray line]; low-risk BCR-ABL1/ABL1≤ 9.84% [n = 211; black
line]). From Marin et al. [51] (reproduced with permission).
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identified that can predict relapse in patients with CML-
CP [65].
Proteomic analysis has identified a group of proteins
expressed at low levels in CML-CP but at high levels
in CML-BC: HSP90, RB, AIF, PP2A, BCL2, XIAP,
SMAD1, SSBP2α, PARP, GAB2, and TRIM24. A re-
verse pattern, high levels in CML-CP but low levels in
BC, has been found for PKC.p664, AKTpT308, actin,
p70S6Kp, Rac1.2.3, PDK1p, MEK, and CDK4 [66].
Other approaches have targeted known genes important
in proliferation, differentiation, or cell survival. One study
found increased expression of CaMKIIγ and HSP70, but
decreased expression of HSP90, in patients with KD muta-
tions compared to those without. Using this expression
pattern, the likelihood of TKI-treated patients harboring
resistant KD mutations could be predicted with a specifi-
city of 82% [67]. These and other efforts are underway
to further relate molecular markers to progression, with
the hope that a greater understanding of their expres-
sion will help guide optimal treatment decisions.Conclusions
With the approval and availability of 3 front line TKIs
and 2 additional TKIs after failure of previous ones for
the treatment of CML, prognostic indicators to guide
treatment selection have become increasingly important.
Given the early state of research, there are few factors
that can guide TKI selection. However, knowledge re-
garding diagnostic systems and genetic, molecular, and
pharmacokinetic markers is advancing rapidly. Ongoing
work continues to illuminate the pathways and genes
that could serve both as prognostic indicators and as
targets for drug development.Convincing data are emerging that early and deep mo-
lecular responses are associated with excellent long-term
outcomes. Patients who do not attain such responses have
poorer prognosis and may benefit from an early change in
treatment. Collectively, this abundance of knowledge
suggests that we should someday be able to pinpoint
the optimal treatment for each individual patient.
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